Both psilocybin and MDMA are becoming more commonly used to treat psychiatric illnesses. However, our understanding of how these novel therapies work is not complete. This study aims improve our understanding of the mechanisms of action of these drugs. 

The primary objective of this project is to investigate psychological, cognitive and physiological changes associated with a single session of psychedelic drug exposure with psilocybin or 3,4-methylenedioxymethamphetamine (MDMA) in a group setting. Specifically, the study aims to use measures of psychological experience, cognitive function and electroencephalography (EEG) before and after psychedelic exposure. Secondary aims are (1) to assess changes in neural activity during acute substance exposure, (2) to determine whether tolerability is similar to previous studies, and (3) to determine whether exposure to psychedelic drugs impacts self-assessed therapist competency.